BioCentury | Jul 13, 2020
Targets & Mechanisms

Verge puts ALS target through COVID-19 paces, leaning on preclinical partners

...neurological aspects of COVID-19, she added. Originally brought to the clinic for autoimmune diseases by Synta Pharmaceuticals Corp....
BioCentury | Apr 12, 2019
Emerging Company Profile

Bright Angel: New hope against fungal resistance

...the need for Bright Angel to selectively target the fungal protein. For example, in 2015 Synta Pharmaceuticals Corp....
BioCentury | Sep 26, 2016
Company News

Madrigal, Tarveda Therapeutics deal

...will be responsible for development costs. Madrigal acquired the platform from its April reverse-merger with Synta Pharmaceuticals Corp....
BioCentury | Sep 5, 2016
Strategy

Back to School 2016: Haste, not waste

As researchers in industry and academia rapidly unravel molecular disease mechanisms and drug developers become more adept at intervening in disease pathways with drugs targeted to specific populations, the current clinical development paradigm cannot keep...
BioCentury | Apr 18, 2016
Company News

Synta, Madrigal deal

...Madrigal and a subsidiary of Synta will reverse-merge as a company focused on non-alcoholic steatohepatitis (NASH...
...subject to approval by Synta shareholders. The parties expect the deal to close in 3Q16. Synta Pharmaceuticals Corp....
BioCentury | Apr 15, 2016
Company News

CV/NASH play Madrigal finds public path via Synta merger

...hormone receptor beta from Roche (SIX:ROG; OTCQX:RHHBY). Madrigal shareholders will receive 253.9 million newly issued Synta...
...64% of the combined company. The shares are valued at about $60.9 million based on Synta's...
...subject to approval by Synta shareholders. The parties expect the deal to close in 3Q16. Synta's...
BioCentury | Apr 7, 2016
Company News

Management tracks

...director and chair of Warp Drive's scientific advisory board. Rigby was SVP and CSO at Synta Pharmaceuticals Corp....
BioCentury | Jan 4, 2016
Finance

Big band swing

...abaloparatide-SC (BA058-SC) to the end of 1Q16. Radius notes that FDA requires 12-month stability data Synta Pharmaceuticals Corp....
BioCentury | Oct 26, 2015
Analyst Picks & Changes

Analyst picks & changes

...Moussatos expects Veltassa revenues of $48.4M in 2016, $150.4M in 2017 and $400.9M in 2018. Synta Pharmaceuticals Corp....
...perform (from outperform) Roth Capital Partners Joe Pantginis Downgrade Neutral (from buy) Peaker downgraded after Synta...
BioCentury | Oct 26, 2015
Clinical News

Ganetespib: Phase III discontinued

...OS vs. docetaxel alone. The combination was generally well tolerated (see BioCentury, March 17, 2014). Synta Pharmaceuticals Corp....
Items per page:
1 - 10 of 312
BioCentury | Jul 13, 2020
Targets & Mechanisms

Verge puts ALS target through COVID-19 paces, leaning on preclinical partners

...neurological aspects of COVID-19, she added. Originally brought to the clinic for autoimmune diseases by Synta Pharmaceuticals Corp....
BioCentury | Apr 12, 2019
Emerging Company Profile

Bright Angel: New hope against fungal resistance

...the need for Bright Angel to selectively target the fungal protein. For example, in 2015 Synta Pharmaceuticals Corp....
BioCentury | Sep 26, 2016
Company News

Madrigal, Tarveda Therapeutics deal

...will be responsible for development costs. Madrigal acquired the platform from its April reverse-merger with Synta Pharmaceuticals Corp....
BioCentury | Sep 5, 2016
Strategy

Back to School 2016: Haste, not waste

As researchers in industry and academia rapidly unravel molecular disease mechanisms and drug developers become more adept at intervening in disease pathways with drugs targeted to specific populations, the current clinical development paradigm cannot keep...
BioCentury | Apr 18, 2016
Company News

Synta, Madrigal deal

...Madrigal and a subsidiary of Synta will reverse-merge as a company focused on non-alcoholic steatohepatitis (NASH...
...subject to approval by Synta shareholders. The parties expect the deal to close in 3Q16. Synta Pharmaceuticals Corp....
BioCentury | Apr 15, 2016
Company News

CV/NASH play Madrigal finds public path via Synta merger

...hormone receptor beta from Roche (SIX:ROG; OTCQX:RHHBY). Madrigal shareholders will receive 253.9 million newly issued Synta...
...64% of the combined company. The shares are valued at about $60.9 million based on Synta's...
...subject to approval by Synta shareholders. The parties expect the deal to close in 3Q16. Synta's...
BioCentury | Apr 7, 2016
Company News

Management tracks

...director and chair of Warp Drive's scientific advisory board. Rigby was SVP and CSO at Synta Pharmaceuticals Corp....
BioCentury | Jan 4, 2016
Finance

Big band swing

...abaloparatide-SC (BA058-SC) to the end of 1Q16. Radius notes that FDA requires 12-month stability data Synta Pharmaceuticals Corp....
BioCentury | Oct 26, 2015
Analyst Picks & Changes

Analyst picks & changes

...Moussatos expects Veltassa revenues of $48.4M in 2016, $150.4M in 2017 and $400.9M in 2018. Synta Pharmaceuticals Corp....
...perform (from outperform) Roth Capital Partners Joe Pantginis Downgrade Neutral (from buy) Peaker downgraded after Synta...
BioCentury | Oct 26, 2015
Clinical News

Ganetespib: Phase III discontinued

...OS vs. docetaxel alone. The combination was generally well tolerated (see BioCentury, March 17, 2014). Synta Pharmaceuticals Corp....
Items per page:
1 - 10 of 312